Harish Shantharam's Insider Trades & SAST Disclosures
Harish Shantharam's most recent trade in Alx Oncology Holdings Inc was a trade of 125,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on April 11, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Harish Shantharam.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alx Oncology Holdings Inc | Harish Shantharam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2025 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Alx Oncology Holdings Inc | Harish Shantharam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 600,000 | 600,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Harish Shantharam | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 360,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Harish Shantharam | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 74,750 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Harish Shantharam | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 20,125 | 0 (0%) | 0% | - | Common Stock | |
| Cymabay Therapeutics Inc | Shantharam Harish | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 74,750 | 74,750 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Harish Shantharam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 20,125 | 20,125 (0%) | 0% | 0 | Common Stock | |
| Cymabay Therapeutics Inc | Harish Shantharam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 360,000 | 360,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges